T1	Participants 224 348	patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy.
T2	Participants 370 417	Patients with measurable and assessable disease
T3	Participants 689 754	A total of 474 patients were treated (239 PLD and 235 topotecan).
T4	Participants 1401 1429	platinum-refractory subgroup
